


UPDATE ON TAFAMIDIS (VYNDAQEL®) MANAGED ACCESS PROTOCOL



The HSE introduced a managed access protocol (MAP) for tafamidis (Vyndaqel®) in March 2022. The aim of the MAP is to provide adult patients with wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM), with access to tafamidis.

By 28th February 2023, the HSE had approved 33 prescribers for tafamidis under this protocol. In March 2023, 80 patients accessed treatment with Tafamidis under the High Tech Arrangement.

June 2023

HSE Medicines Management Programme.